Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Ceretas Enrols First Patient In Phase 2 Alzheimer’s Trial

Ceretas Limited (CTS) · Health care

CTS: $0.900 +4.65% · MC: $67M

Ceretas has enrolled the first patient in its Phase 2 CERE-CALM trial, testing focused ultrasound as a treatment for behavioural symptoms in people with Alzheimer’s disease. The fully funded study is targeting at least 60 participants, with recruitment underway in Sydney and completion anticipated in the first half of 2028. It follows a 12-patient Phase 1 study that reported favourable safety and tolerability, alongside preliminary signs of symptom improvement.

Source announcements: 2026-10-29 09:43 to 2026-10-29 09:43 Sydney time
Story updated 2026-10-29 10:07 Sydney time
SourcesFirst Patient Enrolled in Phase 2 CERE-CALM Clinical Trial
Comments